glp-1 obesity drug news october 9 2025 GLP‑1 real‑world data for obesity: A new standard for metabolic care Lilly hikes revenue forecasts on
Description
The OpenLoop Health data breach (January 2026) affected ~1.6 million records including MEDVi patients
Scheen A
Additional outcomes, including the pathological complete response (pCR), were studied in a retrospective analysis of 347 patients with earlystage triplenegative breast cancer (TNBC) who received KEYNOTE522 and GLP1 RAs or DPP4i treatment at diagnosis and throughout the neoadjuvant period
EC50 values obtained using this method were then used to calculate: sample ratio = sample EC50/EC50 reference peptide-spiked plasma sample and estimated concentration = Known top concentration of peptide- spiked plasma sample/sample ratio
Beyond those standing concerns, in a press announcement dated March 3, 2026 (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 products
